Observing real-world care of patients with transthyretin amyloidosis
Follows adults with ATTR amyloidosis, a rare protein-build-up disease, and their treatments over time.
Plain-language title generated from the registry record
Registry title: Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Key facts
- Where
- Baltimore, Boston, Chicago, Dallas, Danville, Durham, Germantown, Greenville, Houston, Indianapolis, Kansas City, La Jolla, Los Angeles, Manhasset, Milwaukee, Nashville, New Brunswick, New Haven, New York, Philadelphia, Portland, Richmond, Rochester, San Francisco, Seattle, St Louis, and Washington D.C., United StatesSee the 27 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 130 years old?
Source: NCT06465810, who can take part
Where in United States
- BaltimoreBaltimore, United StatesTaking people
- BostonBoston, United StatesTaking people
- ChicagoChicago, United StatesTaking people
- DallasDallas, United StatesTaking people
- DanvilleDanville, United StatesTaking people
- DurhamDurham, United StatesTaking people
- GermantownGermantown, United StatesTaking people
- GreenvilleGreenville, United StatesTaking people
- HoustonHouston, United StatesNot yet recruiting
- IndianapolisIndianapolis, United StatesTaking people
- Kansas CityKansas City, United StatesTaking people
- La JollaLa Jolla, United StatesTaking people
- Los AngelesLos Angeles, United StatesTaking people
- ManhassetManhasset, United StatesTaking people
- MilwaukeeMilwaukee, United StatesTaking people
- NashvilleNashville, United StatesTaking people
- New BrunswickNew Brunswick, United StatesTaking people
- New HavenNew Haven, United StatesTaking people
- New YorkNew York, United StatesNot yet recruiting
- PhiladelphiaPhiladelphia, United StatesTaking people
- PortlandPortland, United StatesTaking people
- RichmondRichmond, United StatesTaking people
- RochesterRochester, United StatesTaking people
- San FranciscoSan Francisco, United StatesTaking people
- SeattleSeattle, United StatesTaking people
- St LouisSt Louis, United StatesTaking people
- Washington D.C.Washington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06465810
- Record updated
- 23 September 2026
- Original description
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.Read full original descriptionShow less
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Inclusion: Patient willing and able to provide written informed consent to participate in the study; Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis; Aged ≥18 years at the time of signing the informed consent; Patient willing and able to participate in collection of electronic patient reported outcomes (PROs).
Exclusion: Concurrent participation in any interventional trial for ATTR amyloidosis; Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA); Involvement in the planning and/or conduct of the current study; Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers.